Literature DB >> 32097093

Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?

Michael A Davies1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32097093      PMCID: PMC7238487          DOI: 10.1200/JCO.20.00136

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Authors:  Y J L Jansen; E A Rozeman; R Mason; S M Goldinger; M H Geukes Foppen; L Hoejberg; H Schmidt; J V van Thienen; J B A G Haanen; L Tiainen; I M Svane; S Mäkelä; T Seremet; A Arance; R Dummer; L Bastholt; M Nyakas; O Straume; A M Menzies; G V Long; V Atkinson; C U Blank; B Neyns
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

3.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Authors:  M B Atkins; L Kunkel; M Sznol; S A Rosenberg
Journal:  Cancer J Sci Am       Date:  2000-02

4.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

5.  Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.

Authors:  V Ellen Maher; Laura L Fernandes; Chana Weinstock; Shenghui Tang; Sundeep Agarwal; Michael Brave; Yang-Min Ning; Harpreet Singh; Daniel Suzman; James Xu; Kirsten B Goldberg; Rajeshwari Sridhara; Amna Ibrahim; Marc Theoret; Julia A Beaver; Richard Pazdur
Journal:  J Clin Oncol       Date:  2019-05-22       Impact factor: 44.544

6.  Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).

Authors:  David R Spigel; Michael McCleod; Robert M Jotte; Lawrence Einhorn; Leora Horn; David M Waterhouse; Ben Creelan; Sunil Babu; Natasha B Leighl; Jason C Chandler; Felix Couture; George Keogh; Glenwood Goss; Davey B Daniel; Edward B Garon; Lee S Schwartzberg; Rohini Sen; Beata Korytowsky; Ang Li; Nivedita Aanur; Maen A Hussein
Journal:  J Thorac Oncol       Date:  2019-05-20       Impact factor: 15.609

7.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Authors:  Caroline Robert; Antoni Ribas; Jacob Schachter; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona M McNeil; Michal Lotem; James M G Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Teresa M Petrella; Omid Hamid; Shu-Chih Su; Clemens Krepler; Nageatte Ibrahim; Georgina V Long
Journal:  Lancet Oncol       Date:  2019-07-22       Impact factor: 41.316

8.  Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.

Authors:  Allison Betof Warner; Jessica S Palmer; Alexander N Shoushtari; Debra A Goldman; Katherine S Panageas; Sara A Hayes; Raazi Bajwa; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Michael A Postow; Paul B Chapman
Journal:  J Clin Oncol       Date:  2020-02-13       Impact factor: 44.544

9.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Authors:  O Hamid; C Robert; A Daud; F S Hodi; W J Hwu; R Kefford; J D Wolchok; P Hersey; R Joseph; J S Weber; R Dronca; T C Mitchell; A Patnaik; H M Zarour; A M Joshua; Q Zhao; E Jensen; S Ahsan; N Ibrahim; A Ribas
Journal:  Ann Oncol       Date:  2019-04-01       Impact factor: 32.976

10.  Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Authors:  Rodabe N Amaria; Sangeetha M Reddy; Hussein A Tawbi; Michael A Davies; Merrick I Ross; Isabella C Glitza; Janice N Cormier; Carol Lewis; Wen-Jen Hwu; Ehab Hanna; Adi Diab; Michael K Wong; Richard Royal; Neil Gross; Randal Weber; Stephen Y Lai; Richard Ehlers; Jorge Blando; Denái R Milton; Scott Woodman; Robin Kageyama; Daniel K Wells; Patrick Hwu; Sapna P Patel; Anthony Lucci; Amy Hessel; Jeffrey E Lee; Jeffrey Gershenwald; Lauren Simpson; Elizabeth M Burton; Liberty Posada; Lauren Haydu; Linghua Wang; Shaojun Zhang; Alexander J Lazar; Courtney W Hudgens; Vancheswaran Gopalakrishnan; Alexandre Reuben; Miles C Andrews; Christine N Spencer; Victor Prieto; Padmanee Sharma; James Allison; Michael T Tetzlaff; Jennifer A Wargo
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

View more
  4 in total

Review 1.  Anti-PD-1: When to Stop Treatment.

Authors:  Y Jansen; A A M van der Veldt; G Awada; B Neyns
Journal:  Curr Oncol Rep       Date:  2022-03-26       Impact factor: 5.945

2.  Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report.

Authors:  Jianhua Rao; Jinguo Xia; Wenjie Yang; Chen Wu; Bowen Sha; Qitong Zheng; Feng Cheng; Ling Lu
Journal:  Ann Transl Med       Date:  2020-12

3.  Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Authors:  E E A P Mulder; K de Joode; S Litière; A J Ten Tije; K P M Suijkerbuijk; M J Boers-Sonderen; G A P Hospers; J W B de Groot; A J M van den Eertwegh; M J B Aarts; D Piersma; R S van Rijn; E Kapiteijn; G Vreugdenhil; F W P J van den Berkmortel; E Oomen-de Hoop; M G Franken; B Ryll; P Rutkowski; S Sleijfer; J B A G Haanen; A A M van der Veldt
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

Review 4.  What is the optimal duration of immune checkpoint inhibitors in malignant tumors?

Authors:  Jiaxin Yin; Yuxiao Song; Jiazhuo Tang; Bicheng Zhang
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.